Welcome to the UPF Digital Repository

Patient-centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA-EAACI approach - ARIA-EAACI Task Force Report

Show simple item record

dc.contributor.author Bousquet, Jean
dc.contributor.author Antó i Boqué, Josep Maria
dc.contributor.author Ollert, Markus
dc.date.accessioned 2023-09-28T06:20:39Z
dc.date.available 2023-09-28T06:20:39Z
dc.date.issued 2023
dc.identifier.citation Bousquet J, Shamji MH, Anto JM, Schünemann HJ, Canonica GW, Jutel M, et al. Patient-centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA-EAACI approach - ARIA-EAACI Task Force Report. Allergy. 2023 Jul;78(7):1758-76. DOI: 10.1111/all.15740
dc.identifier.issn 0105-4538
dc.identifier.uri http://hdl.handle.net/10230/57984
dc.description.abstract Biomarkers for the diagnosis, treatment and follow-up of patients with rhinitis and/or asthma are urgently needed. Although some biologic biomarkers exist in specialist care for asthma, they cannot be largely used in primary care. There are no validated biomarkers in rhinitis or allergen immunotherapy (AIT) that can be used in clinical practice. The digital transformation of health and health care (including mHealth) places the patient at the center of the health system and is likely to optimize the practice of allergy. Allergic Rhinitis and its Impact on Asthma (ARIA) and EAACI (European Academy of Allergy and Clinical Immunology) developed a Task Force aimed at proposing patient-reported outcome measures (PROMs) as digital biomarkers that can be easily used for different purposes in rhinitis and asthma. It first defined control digital biomarkers that should make a bridge between clinical practice, randomized controlled trials, observational real-life studies and allergen challenges. Using the MASK-air app as a model, a daily electronic combined symptom-medication score for allergic diseases (CSMS) or for asthma (e-DASTHMA), combined with a monthly control questionnaire, was embedded in a strategy similar to the diabetes approach for disease control. To mimic real-life, it secondly proposed quality-of-life digital biomarkers including daily EQ-5D visual analogue scales and the bi-weekly RhinAsthma Patient Perspective (RAAP). The potential implications for the management of allergic respiratory diseases were proposed.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Wiley
dc.relation.ispartof Allergy. 2023 Jul;78(7):1758-76
dc.rights © 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
dc.rights.uri http://creativecommons.org/licenses/by-nc/4.0/
dc.title Patient-centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA-EAACI approach - ARIA-EAACI Task Force Report
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1111/all.15740
dc.subject.keyword ARIA
dc.subject.keyword EAACI
dc.subject.keyword Apps
dc.subject.keyword Digital health
dc.subject.keyword Rhinitis
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

In collaboration with Compliant to Partaking